Skip to main content

Summary

for people ages 18–99 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Official Title

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Details

This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.

Keywords

NSCLC Non-small Cell Lung Cancer Lung Cancer anti-CTLA-4 anti-PD-L1 immunotherapy IMTC Lung Neoplasms Carcinoma, Non-Small-Cell Lung Antibodies, Monoclonal Tremelimumab

Eligibility

You can join if…

Open to people ages 18–99

  1. Age ≥ 18 years
  2. Advanced non-small cell lung cancer
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  4. Adequate organ and marrow function

You CAN'T join if...

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
  2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs
  3. Active or prior documented autoimmune disease within the last 2 years.

Locations

  • Research Site
    San Francisco, California, 94115, United States
  • Research Site
    Los Angeles, California, 90025, United States
  • Research Site
    Los Angeles, California, 90095, United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedImmune LLC
ID
NCT02000947
Phase
Phase 1/2
Lead Scientist
Thierry Jahan
Study Type
Interventional
Last Updated
September 22, 2017